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Introduction
One of the most common disorders that affects women 
is polycystic ovarian syndrome (PCOS). The classic form 
of this syndrome includes amenorrhoea, anovulation, 
infertility, hirsutism, obesity and enlarged bilateral 
ovaries with cysts.1 Obesity has been found in at least 
50% of women with PCOS. These patients usually have 
central (android) body fat distribution. Android obesity, 
which is characterised by an increased waist-to-hip 
ratio (> 0.80), leads to an increased risk of diabetes 
mellitus and cardiovascular disease.2 One study 
showed that the prevalence of obesity in women with 
PCOS increased from 51% between 1987 and 1990 
to 74% between 2000 and 2002.3 In addition, insulin 
resistance and hyperinsulinaemia commonly occur 
in patients with PCOS. In these cases, the rate of IGT 
and diabetes mellitus type 2 is 16-35% and 5-17%, 
respectively. These rates slightly increase, even in non-
obese women, with PCOS.3
In addition, insulin resistance and hyperinsulinaemia 
commonly occur in patients with PCOS. In these cases, 
the rate of IGT and diabetes mellitus type 2 is 16-35% 
and 5-17%, respectively. These rates slightly increase, 
even in non-obese women, with PCOS.25
Lipoprotein abnormalities are also common in PCOS. 
Disorders that relate to lipoprotein abnormalities include 
elevated levels of total cholesterol, triglycerides and 
low-density lipoprotein (LDL), as well as decreased levels 
of high-density lipoprotein (HDL) and apolipoprotein 
AI. Other observations in women with PCOS include 
an increased incidence of hypertension over time to 
a rate of 40% around menopause, a higher incidence 
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Abstract
Objectives: Women with polycystic ovarian syndrome (PCOS) are at twice the risk of developing metabolic 
syndrome, compared to women from the general population. The aim of this study was to assess the prevalence 
of metabolic syndrome in the first-degree relatives (fathers) of patients suffering from PCOS.
Design: This was a case control study.
Setting and subjects: The study was conducted on 34 fathers of women with PCOS who presented at gynaecological 
clinics in Shiraz, Iran (as the case group), and 34 fathers of healthy women (as the control group). 
Outcomes measures: Metabolic syndrome was determined according to Adult Treatment Panel III (ATP III) and 
International Diabetes Federation (IDF) indices. A blood sample was obtained to assay serum insulin, blood sugar, 
testosterone and lipoproteins. The data were analysed using independent t-test, Fisher’s exact test and the chi-
square test. 
Results: According to the ATP III index, the prevalence of metabolic syndrome was 29.35% in the fathers of the PCOS 
patients and 8.8% in the fathers of women in the control group (p-value < 0.05). According to the IDF index, this 
rate was 17.41 in the fathers of patients with PCOS (p-value < 0.05). According to the quantitative insulin sensitivity 
check and homeostasis model insulin resistance indices, the prevalence of insulin resistance, hypertension, type 2 
diabetes and hypercholesterolaemia was higher in the fathers of patients with PCOS than in the control group, but 
the difference was not significant (p-value > 0.05).  
Conclusion: The fathers of the women with PCOS were at a higher risk of developing metabolic syndrome, 
hypertension, dyslipidaemia, impaired glucose tolerance and diabetes.
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of atherosclerosis and cardiovascular disease, and 
increased risk of myocardial infarction. Other PCOS 
complications include sleep apnoea and infertility.2 
The high familial incidence of the disease suggests its 
genetic origin, but there is limited information on the 
involved gene or genes.4 This disease is among the most 
significant causes of mortality. The risk of developing 
atherosclerotic cardiovascular disease5 and type 2 
diabetes mellitus is likely with metabolic syndrome.6 
Moreover, coronary artery disease accounts for nearly 
50% of all yearly deaths in Iran.7 
The prevalence of PCOS varies from 4-10%,8-10 up to 17-
22%,11-12 depending on the criteria used.
Since no studies have been conducted on this issue 
in Iran, this study was designed to investigate the rate 
of metabolic syndrome in the fathers of patients with 
PCOS presenting at gynaecology clinics in Shiraz, Iran.
Method
Patients with clinical PCOS were identified. Their 
fathers, aged 30 years and older, who met the inclusion 
criteria of the study, were interviewed and the first 
part of a questionnaire, which included demographic 
information, was completed. Individuals who fulfilled 
the inclusion criteria of the study and who provided 
written informed consent to take part in the research 
were considered to constitute the experimental group. 
The control group included fathers of women with no 
history of PCOS, nor no history of it in their families. A full 
history, which included information on the regularity of 
menstrual periods and records of hirsutism and infertility, 
was obtained. Women were included in the study as 
controls if they met the inclusion criteria of not smoking, 
having no history of PCOS, being over 30 years old, and 
not using drugs to control blood sugar, blood lipids and 
blood pressure, as well as free testosterone. 
In this study, 17 brothers and 34 fathers were selected 
as the case group. Thirty-four fathers were chosen as 
the control group according to the insulin index13 and 







Blood pressure, body mass index (BMI) and the waist-
hip index were measured in both groups. The subjects’ 
weight was determined when wearing minimum 
clothing and no shoes, using digital scales, with minimum 
error of approximately 100 g. In addition, their height 
was measured while in a standing position, without 
shoes, using a tape measure. BMI was calculated by 
dividing the weight in kilogrammes by the squared 
height in metres.  BMI ≥ 18.5 kg/m2 and < 25 kg/m2 was 
considered to be normal, 25-29.9 kg/m2 overweight, 30-
34.9 kg/m2 obese (class I), 35-39.9 kg/m2  obese (class II), 
and ≤ 40 kg/m2 obese (class III).14-15
Waist-to-hip index was also determined while standing. 
The waist circumference was measured from the 
lowest rib margin and iliac crest (umbilical area) at the 
end of exhalation and the hip circumference over the 
widest area of the gluteal region (the widest femoral 
circumference). If the ratio of these two measurements 
(waist to hip) was more than 0.85 in women and 0.9 
in men, it was considered to constitute central obesity 
(android obesity).16
After 15 minutes, blood pressure was measured by 
means of a sphygmomanometer matched to the arms 
diameter while the patients were sitting on a chair 
with no cover, with their right arms at a 45-degree 
angle to their chests and their elbows matched to 
the arm’s diameter. The bag pressure gauge was tied 
2.5 cm above the elbows. Blood pressure was measured 
twice from the right arm with a 10-minute interval 
and its mean was recorded as the blood pressure. 
Blood pressure that was equal to, or higher than, 
140/90 mmHg was diagnosed as hypertension.
Before testing, patients were reminded not to use drugs 
that might affect their blood sugar and blood pressure, 
including acetaminophen, benzodiazepines and beta 
blockers, oral contraceptive pills, phenytoin or thiazide 
diuretics, the night and the morning before the tests. 
Overnight fasting of 12-10 hours before the test was 
necessary for participants.   
Blood samples were obtained from participants 
between 7h00 and 9h00, and the samples centrifuged 
according to standard protocols 30-45 minutes 
later. To perform the oral glucose tolerance test, 
75 g monohydrate glucose, soluble in water, was 
administered orally to the participants. Fasting blood 
glucose, fasting insulin, free blood testosterone, 
triglycerides, total cholesterol, and LDL and HDL were 
also measured in the subjects. Serum was used to gauge 
insulin. However, since insulin is only stable at -8°C for 
2-24 hours, a freezer with a temperature of -70°C 
was used to store it over the long term. After 
collecting the samples, insulin was measured using 
the radioimmunoassay method and the Mercodia 
kit (Sweden). Based on this kit, the natural insulin 
level was considered to be 2-25 MIU/l. Fasting blood 
glucose, triglycerides, cholesterol and testosterone 
were measured according to the calorimetrically 
enzymatic method, using Pars test kits (Tehran, 
Iran). HDL and LDL levels were also analysed using 
the immunoturbidometry test (Pars, Iran) method 
utilising a joint device. Triglycerides ≥ 150 mg/dl, HDL 
< 40 mg/dl in males, HDL < 50 mg/dl in females, and LDL 
≥ 160 mg/dl were considered to be abnormal results. 
Fasting blood glucose tests and two-hour blood sugar 
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(oral glucose tolerance test) were assessed according 
to World Health Organization (WHO) criteria. 
Impaired glucose tolerance (IGT) was evaluated using 
the following criteria:17
Glucose intolerance: > 140 mg/dl and < 200 mg/dl .
Diabetes mellitus: > 200 mg/dl.
Fasting plasma glucose: > 100 and < 126 mg/dl.
Diabetes mellitus: fasting glucose > 126 mg/dl.
To assess insulin resistance, homeostasis model insulin 
resistance (HOMA) and quantitative insulin sensitivity 
check index (QUICK) indices were used. The HOMA 
index was devised by Mato et al in 1985. 
Fasting plasma glucose and fasting insulin levels were 
calculated according to the following formulas:18-23 
HOMA = [fasting insulin (µU/ml) fasting glucose 
(mmol/l)]/22.5.
HOMA = [fasting insulin (mU/l) x fasting glucose (mg/
dl)/405.
In 2000, a new index, QUICK, was devised by Katz et 
al to assess insulin sensitivity and which had a better 
correlation with direct standard methods than the 
HOMA index.
This index was also calculated by using glucose and 
fasting insulin serum:
QUICK = 1/[log fasting insulin(µU/ml)+ log fasting 
glucose in (mg/dl)].
The subjects with HOMA  ≥ 2.38, QUICK ≤ 0.33, or fasting 
insulin ≥ 10.58 (μU/ml), were considered to be insulin 
resistant.24-25
In this study, Adult Treatment Panel III (ATP III), 
International Diabetes Federation (IDF) and HOMA 
criteria were used to investigate metabolic syndrome. 
According to the ATP III index, the diagnostic criteria 
for metabolic syndrome are listed below. Having three 
of the following disorders equates to a diagnosis of 
metabolic syndrome:
•	 Abdominal obesity (waist circumference):  
Men >102 cm and women > 88 cm.
•	 Blood pressure: ≥ 130/≥ 85 mmHg.
•	 Triglycerides: ≥ 150 mg/dl.
•	 HDL cholesterol: Men < 40 mg/dl and women  
< 50 mg/dl.
•	 Fasting glucose: ≥ 110 mg/dl.26
According to the IDF index, the diagnostic critera for 
metabolic syndrome are as follows:
•	 Abdominal obesity (waist circumference):  
Men > 90 cm and women > 80 cm.
•	 Blood pressure: ≥ 130/≥ 85 mmHg.
•	 Triglycerides: ≥ 150 mg/dl.
•	 HDL cholesterol: Men < 40 mg/dl and women  
< 50 mg/dl.
•	 Fasting glucose: ≥ 100 mg/dl.27
P-values less than 0.05 were considered to be stat-
istically significant.
According to the tests results, subjects with insulin 
resistance, abnormal glucose intolerance, elevated 
testosterone, high LDL and triglycerides, low HDL or high 
blood pressure were identified, provided with individual 
counselling and referred to an endocrinologist for 
further examination.
Results
In this study, no statistically significant difference was 
found between the two groups with regard to age 
(p-value < 0.05). According to the ATP III criteria, the 
Table I: Distribution of insulin resistance in the fathers according to the homeostasis model insulin resistance index, quantitative insulin 
sensitivity check index, and insulin fasting index, in the study population
Frequency group
Controls, n = 34 Experimental, n = 34
IR Without IR IR Without IR
Number Percentage Number Percentage Number Percentage Number Percentage
According to HOMA index 2 5.8 32 94.11 5 14.7 29 85.3
According to QUICK index 2 8.82 31 91.77 7 20.6 27 79.4
According to IF index 1 2.94 33 97.05 4 11.76 30 88.23
HOMA: homeostasis model insulin resistance, IF: insulin fasting, IR: insulin resistance, QUICK: quantitative insulin sensitivity check
Table II: Comparison of metabolic syndrome in the fathers of women with polycystic ovarian syndrome and the controls
Group metabolic syndrome
Experimental, n = 34
Metabolic syndrome
Controls, n = 34
Metabolic syndrome Statistical 
value
Number Percentage Number Percentage
Metabolic syndrome according to ATP III indices 12 35.29 3 8.8 0.008
Metabolic syndrome according to IDF indices 14 41.17 4 11.76 0.007
ATP III: Adult Treatment Panel III,  IDF: International Diabetes Federation   
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rate of metabolic syndrome was 35.29% and 8.8% in 
the fathers of women with PCOS and in the controls, 
respectively. A fourfold increase was observed in the 
case group in terms of the risk of having metabolic 
syndrome. According to the IDF diagnostic criteria, 
the incidence of metabolic syndrome was 41.17% in 
the case group, and 11.76% in the controls, and the 
difference was statistically significant (p-value < 0.05). 
Glucose intolerance and blood pressure were higher in 
the fathers of the case group, compared to the control 
group, and the difference was statistically significant 
(p-value < 0.05). According to the HOMA and QUICK 
indices, insulin resistance in the relatives of women with 
PCOS was higher than it was in the controls (p-value 
≥ 0.05). Also, fasting insulin was higher in the case 
group than it was in the control group. However, the 
difference was not statistically significant (p-value 
≥ 0.05) (Tables I-III).
Discussion 
PCOS is one of the most common endocrine disorders 
affecting premenopausal women. The prevalence of 
this disorder varies from 4-12% worldwide. Metabolic 
syndrome is defined by metabolic indices, such 
as abdominal obesity (central obesity), insulin 
resistance, elevated blood glucose, dyslipidaemia 
and hypertension. Patients suffering from metabolic 
syndrome are at high risk of developing cardiovascular 
disease.28 According to the WHO and IDF, metabolic 
syndrome is associated with a 2.69 (2.45-2.95) and 
2.20 (2.03-2.38) increase, respectively, in the risk of 
myocardial infarction.29 In comparison to normal men 
and women, patients with metabolic syndrome are at 
greater risk (127%) of acquiring cardiovascular disease 
and having strokes, ischaemic heart disease and 
diabetes.30 According to studies conducted in Turkey 
in recent years, the first-degree relatives of patients 
with PCOS are an at-risk group.31 Nevertheless, to the 
best of our knowledge, no Iranian studies have been 
performed in this field. 
Thus, the present study was designed to determine the 
incidence of metabolic syndrome in the first-degree 
relatives (fathers) of patients with PCOS. According to 
the ATP III criteria, the rate of metabolic syndrome was 
four times higher in the case group fathers compared 
to the control group, and the difference was statistically 
significant (p-value = 0.008). According to the IDF 
criteria, the rate of metabolic syndrome was significantly 
higher in the fathers of the experimental group than in 
the controls (p-value = 0.007). Similar results were also 
obtained in other studies that addressed this issue.
In a study conducted by Benitz, the incidence of 
metabolic disorders was 62.5% in the first-degree 
relatives of patients with PCOS, and 27.8% in those of 
subjects in the control group (p-value < 0.05).13
Metabolic syndrome is highly prevalent worldwide and 
10-20% of non-diabetics suffer from this syndrome.32 The 
results of the study by Camacho indicated that 23.7% 
of American adults were affected by this syndrome.33 
Moreover, in Covielli’s study, the incidence of the 
disorder was 42% in the relatives of patients with PCOS 
versus 32% in the relatives of subjects in the control 
group.34 In another study, the incidence was estimated 
to be 40% in men and 29% in women.35
Shiwaku conducted a study to determine the 
prevalence of metabolic syndrome in workers from 
Japan, Korea and Mongolia using the ATP III criteria.36 
The incidence of this syndrome was approximately 
13%, 14%, and 19% in Japanese, Korean, and 
Mongolian men, respectively. Also, the prevalence 
of metabolic syndrome was approximately 12%, 12%, 
and 14% in Japanese, Korean and Mongolian women, 
respectively.36
Mortality from heart disease and diabetes is higher 
in patients with this disorder than it is in the normal 
population.37
Metabolic syndrome may be viewed as a bridge 
between diabetes and heart disease because 
approximately 50% of patients with type 2 diabetes 
suffer from metabolic syndrome. Therefore, they 
are more likely to suffer from disorders such as 
strokes, retinopathy and neuropathy, and to have 
microalbuminuria.38
To evaluate the agreement between the ATP III and 
IDF methods of diagnosing metabolic syndrome, the 
Kappa test was used. The results revealed significant 
agreement between the two methods (kappa = 
81.5%).
The average fasting blood glucose in the fathers of the 
control group was lower than that in the experimental 
Table III: Comparison of diabetes, blood pressure and cholesterol incidence in the experimental and control groups
Group complication
Experimental, n = 34 Controls, n = 34 Statistical 
valueNumber Percentage Number Percentage
Type 2 diabetes 10 29.4 3 8.8 0.06
Hypertension 5 14.7 2 5.8 0.04
High cholesterol 6 17.6 3 8.8 0.6
Furthermore, LDL levels were increased in the fathers of the case group, compared to those in the control group. However, the difference was not statistically significant  
(p-value = 0.6).
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group (p-value < 0.05). Our results were similar to 
those reported by Sir-Petermann et al. In that study, 
the mean of fasting blood sugar was higher in the 
fathers of women with PCOS than it was in the fathers 
of the healthy women (controls).39 Similar results were 
obtained by Benitz et al.13
According to the WHO criteria, the rate of IGT was 5.8% 
in the fathers of the control group (n = 2) and 26.7% 
in the experimental group (n = 9) and the difference 
was considered to be statistically significant (p-value 
= 0.04). In other studies, the rate of IGT was 31% in the 
fathers of the group with PCOS; significantly higher than 
that in the first-degree relatives of the control subjects 
(p-value < 0.05).39-41 In a Turkish study, 52% of the fathers 
of the women with PCOS, and 15% of the control group 
fathers, had IGT (p-value < 0.05).40
In a study by Yilmaz et al, the prevalence of diabetes 
mellitus, IGT, and impaired fasting glucose was 17.5%, 
17.5% and 5%, respectively, in mothers with PCOS, and 
21%, 28% and 5% in the fathers. Overall, the control 
group had 15% IGT. The difference between the first-
degree relatives of the patients with PCOS and those 
of the control group was found to be statistically 
significant (p-value < 0.001).42
Kang et al stated that glucose intolerance was one of 
the modifiable risk factors for diabetes.41 Approximately 
50-70% of women with PCOS, and 80-100% of patients 
with type 2 diabetes mellitus, had variable degrees of 
insulin resistance. Also, women with PCOS had a 5-10 
times higher risk of developing diabetes, compared to 
their matched controls.43
In this study, the mean total cholesterol in the case 
group was significantly higher than that in the control 
group (p-value = 0.001), which is consistent with the 
results obtained in another study performed in the 
endocrinology section of Chil University.36  In that study, 
the fathers of women with PCOS had higher total 
cholesterol than the fathers of the healthy women 
(p-value < 0.05).44
Sir-Petermann et al conducted a study at the University 
of Chil in Santiago to investigate glucose tolerance and 
insulin resistance in the parents of patients with PCOS, 
compared to that in the parents of healthy women.39 
According to the results, the incidence of type 2 
diabetes was 1.89-fold higher in the parents of patients 
with PCOS than it was in the control group. Insulin 
resistance was also significantly higher in the parents 
of the women with PCOS, compared to the control 
group. A significant difference was also observed 
between the two groups with regard to metabolic 
parameters.39 Based on the results of clinical studies 
conducted on the issue, the development of diabetes 
can be prevented by maintaining proper sugar levels.45
In the current study, hypertension was diagnosed 
in 5.8% (n = 2) of the control group and in 14.7% 
(n = 5) of the experimental group, and the difference 
was considered to be statistically significant (p-value 
= 0.04). In the study by Benitz et al, the incidence 
of hypertension was also significantly higher in the 
fathers of the women with PCOS, than it was in the 
control group (9.3% vs. 18.7%) (p-value < 0.05).13 In the 
current study, hypertension was diagnosed in 5.8% 
(n = 2) of the control group, and 14.7% (n = 5) of the 
experimental group. The difference was statistically 
significant (p-value = 0.04). In the study by Benitz et al, 
the incidence of hypertension was also significantly 
higher in the fathers of the women with PCOS than 
it was in the control group (9.3% vs. 18.7%), (p-value 
< 0.05).13
Research limitations
Mental and physical tension, as well as the dietary 
habits of people, have an effect on the incidence 
of metabolic syndrome. Despite using the random 
sampling method, this aspect of the study was out of 
the researchers’ control. Another limitation was its small 
sample size. Thus, it is recommended that further studies 
are conducted using larger populations.
Conclusion
Metabolic syndrome  is a constellation of cardiometa-
bolic risk factors, including insulin resistance, hypergly-
caemia, dyslipidaemia, hypertension and myocardial 
infarction.45-49 According to the results of this study, the 
families (fathers) of patients with PCOS consititute a 
high-risk group and should be screened regularly. As 
well as the patients suffering from PCOS, the first-degree 
relatives should also be evaluated for components of 
metabolic syndrome. 
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